BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced today that independent lab test results conducted at Microbiotest Inc. of Sterling, Virginia demonstrated that Ygiene™ Hospital Grade Antimicrobial totally eradicated the H1N1 Swine Flu virus in 20 seconds (Virtual Contact). This independent testing shows that Ygiene™ Hospital Grade Antimicrobial is extremely effective against the Swine Flu. BioNeutral’s Ygiene™ Hospital Grade Antimicrobial is also one of a few antimicrobials actually tested against the specific H1N1 Swine Flu Virus.

On June 11th the World Health Organization (WHO) declared that the original outbreak of Swine Flu (H1N1) had progressed unabated to a global pandemic Level 6, meaning that isolation and control of human to human infection within a single nation or global region was not possible. Current concerns with the Swine Flu are that it may return to North America this fall in an even more resilient viral form. While many current commercial antimicrobials are believed to be effective against the Swine Flu Virus, only a handful have actually been tested against the H1N1 (Swine Flu) Virus. If the Swine Flu Virus reappears in a more resilient mutated viral form, the likelihood increases that the untested antimicrobials currently on the market may not be effective against this virus. In addition, many of today’s commercial antimicrobials require an extremely long contact time of 10 minutes to be effective against the flu virus. In contrast, the Ygiene™ Hospital Grade Antimicrobial, developed by BioNeutral, requires only 20 seconds of contact time, making cleaning and elimination of the virus more realistic in today’s world where speed is of the essence. The speed of BioNeutral’s Ygiene™ Hospital Grade Antimicrobial will meet these time to kill demands.

Recently, former Secretary of Homeland Security, Michael Chertoff and Dr. J. Bennet Waters wrote an article about the problems and issues associated with a pandemic. In the article ( they explain that using old conventional thinking and “treating a pandemic as a health problem is not just bad policy, it is a dangerous approach." Associated with a pandemic are a myriad of diplomatic, economic and national security consequences along with complex operational issues at all levels, in all sectors. Plans to deal with a pandemic must include prevention, detection, response and recovery. BioNeutral believes that its Ygiene™ Hospital Grade Antimicrobial will be an integral part of a comprehensive plan that deals with a pandemic such as the Swine Flu.

BioNeutral Group CEO, Stephen J. Browand, stated "Ygiene is an inexpensive, Green to the environment, non corrosive, non-staining, mild to the touch chemical formulation, which out performs all other antimicrobials and will become the solution of choice once approved by the EPA for commercialization in the United States. The company is in discussions to distribute and license its groundbreaking technology which includes a family of formulations that are all sporicidal.”

Chief Scientist at BioNeutral Group, Dr. Andy Kielbania stated “These independent lab results continue to verify the exceptional efficacy and speed to kill of our Ygiene™ Hospital Grade Antimicrobial. In addition, our strategy of raising the bar on antimicrobial performance includes actually testing against the microorganisms where we intend to make our EPA claims. We prefer not to make claims by extrapolating scientific data since this approach may lead to invalid conclusions.” He continued, “We also believe for an antimicrobial to be effective it must eradicate quickly like the 20 seconds demonstrated by our Ygiene™ Hospital Grade. Based upon all the independent testing results obtained to date on our Ygiene™ antimicrobial, we believe it will also be extremely effective and have a beneficial toxicity profile and a significant cost performance advantage when used in a diluted form against the H1N1 virus. We are currently pursuing this approach. The 10 minute required contact time claimed by many of today’s commercial disinfectants is much too long since those individuals responsible for cleaning areas may not rigorously follow these extended time requirements. Developing our world class antimicrobials with rapid kill times is an important part of our strategy of raising the bar on today’s antimicrobial performance.”

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at

About Microbiotest Inc.

Microbiotest Inc. located in Sterling Virginia is a world recognized laboratory with over 20 years of experience in testing a broad spectrum of microbiological materials. Microbiotest effectively collaborates and has an excellent track record with its clients that are developing new products to meet various Agency regulatory requirements using recognized protocols both in North America and abroad. In addition Microbiotest has the ability to design unique tests for special situations.

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.